KR101426888B1 - Compositions for Anti-Avian Influenza virus - Google Patents

Abstract

The present invention provides an anti-bird flu virus composition and an anti-avian influenza virus composition comprising ginseng or red ginseng extract, saponin or acid polysaccharide as an active ingredient. The active ingredient used in the present invention promotes the secretion of interferon-alpha (interferon-alpha) and interferon-gamma (interferon-gamma) involved in antivirus and inhibits the proliferation of avian influenza virus. This antiviral effect effectively reduces the mortality rate for avian influenza virus infection. In addition, pharmaceuticals, functional foods, or food compositions can be prepared as active ingredients of the present invention.

Red ginseng, saponin, avian flu, H5N1, interferon

Description

Compositions for Anti-Avian Influenza virus < RTI ID = 0.0 >

The present invention relates to an Avian influenza virus composition for inhibiting Avian influenza virus proliferation and an anti-avian influenza virus composition comprising ginseng or red ginseng extract, saponin or acid polysaccharide as an active ingredient.

Influenza virus (Influenza virus) belongs to the family Orthomyxoviridae, and its serotype is divided into three types A, B, and C. Among them, type A infection has been identified in humans, horses, pigs, other mammals and various species of poultry and wild birds (Selmons et al ., Avian Dis ., 18 (1): 119-124 (1974); Turek R et al ., Acta Virol ., 27 (6): 523-527 (1983); Webster RG et al ., Microbiol Rev. , 56 (1): 152-179 (1992)). The serotypes of influenza A viruses are classified according to the types of biological proteins such as hemagglutinin (HA) and neuraminidase (NA), which are two proteins on the virus surface, and 144 types (HA protein 16 species and 9 kinds of NA proteins). HA plays a role in attachment of somatic cells to viruses, and NA allows viruses to penetrate into cells (Alexander DJ, Vet . Microbiol ., 74 (1-2): 3-13 (2000)).

The normal natural host of the influenza A virus is known as a wild waterbird such as a duck or a gull. As a result of the influenza infection epidemiological survey on wild birds all over the world, all 16 kinds of HA type and 9 kinds of NA type influenza It has been confirmed that the virus is infected in wild birds (Selmons et al ., Avian Dis ., 18 (1): 119-124 (1974)). The avian influenza virus classified as type A is a common communicable disease virus. It is a non-pathogenic avian influenza that causes mild respiratory symptoms when it is infected with a chicken due to its pathogenicity, a mortality rate of about 1-30% There are three major types of avian influenza (LPAI) and highly pathogenic avian influenza (HPAI), which have a high mortality rate of 95% or more and are also referred to as "Bird flu" (Alexander DJ, Vet . Microbiol ., 74 (1-2): 3-13 (2000)). The highly pathogenic avian influenza is classified as Class A in the International Bureau of OIE (OIE) and as a livestock epidemic in Korea.

Since the 1980s, highly pathogenic avian influenza (HPAI) has been confirmed worldwide, including the United States, Australia, Pakistan and Hong Kong. In particular, sera A / H5N1 highly pathogenic avian influenza viruses occurred in almost all simultaneously in Southeast Asia and Far East Asia including Vietnam, Japan, and Thailand in December 2003, starting in Korea in December 2003. Especially, the highly pathogenic avian influenza virus in Vietnam and Thailand has been confirmed to be a mutated avian influenza virus (mutant type A / H5N1 HPAI) virus which can be infected with human when contacted with infected birds, unlike the traditional highly pathogenic avian influenza virus (Song CS et al ., Korean J. Poult. Sci ., 31 (2): 129-136 (2004)).

Influenza viruses infect the respiratory system, causing systemic symptoms, periodic changes in appearance, and not killing the host, but moving to another host before the host dies. Although the vaccine has been developed against it, The magazine is not available yet, and the fundamental virus treatment is not done yet.

On the other hand, amantadine and rimantadine inhibit the function of M2 ion channel protein of influenza virus and are typical antiviral agents for inhibiting the proliferation of influenza virus in vivo. However, these two antiviral agents have been found to have a disadvantage that mutant viruses that do not affect the ion channel function of the influenza virus M2 protein occur very easily. Zanamivir and oseltamivir (Tamiflu), developed to overcome these shortcomings, inhibit the function of the neuraminidase protein of influenza virus and inhibit the growth of influenza virus in vivo Are typical antiviral agents. However, there is a disadvantage that Zanamivir should be administered by inhalation and intravenous injection. Ocelaminivir can be administered orally, but it has been pointed out as a disadvantage due to recent reports of the emergence of resistant virus and side effects such as vomiting and dizziness when administered orally (Ward P et al ., J. Antimicrob . Chemother ., 55: 15-121 (2005)).

The development of highly immunogenic pandemic H5N1 avian influenza virus pandemic, along with vaccines and remedies, will increase the immunity of humans. Therefore, it is necessary to study the feasibility of prevention or defense against avian influenza by testing the effectiveness of red ginseng against avian influenza as a substance enhancing immunity against avian influenza virus.

A number of patent documents are referred to throughout this specification and their citations are indicated. The disclosures of the cited patent documents are hereby incorporated by reference herein in their entirety to better illustrate the state of the art to which the invention pertains and the teachings of the present invention.

The present inventors have sought to develop a vaccine and a therapeutic agent and a substance that increases immunity when a pandemic caused by the avian influenza virus occurs. As a result, it was confirmed that ginseng or red ginseng extract, saponin or acid polysaccharide inhibits the proliferation of avian influenza virus by promoting the secretion of interferon having antiviral action, thereby completing the present invention.

Accordingly, an object of the present invention is to provide a composition for inhibiting Avian influenza virus proliferation.

Another object of the present invention is to provide an anti-avian influenza virus composition.

Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims and drawings.

According to one aspect of the present invention, there is provided a composition for inhibiting Avian influenza virus proliferation comprising ginseng or red ginseng extract, saponin or acid polysaccharide as an active ingredient.

According to another aspect of the present invention, there is provided an anti-avian influenza virus composition comprising ginseng or red ginseng extract, saponin or acid polysaccharide as an active ingredient.

The present inventors have sought to develop a vaccine and a therapeutic agent and a substance that increases immunity when a pandemic caused by the avian influenza virus occurs. As a result, it was confirmed that ginseng or red ginseng extract, saponin or acid polysaccharide promotes the secretion of interferon having antiviral action, thereby inhibiting the proliferation of avian influenza virus.

According to the present invention, ginseng or red ginseng extract, saponin or acid polysaccharide is used as an active ingredient.

The term "Ginseng" herein goryeosam (Panax ginseng , P. quiquefolius , P. notoginseng , P. japonicus , P. trifolium , P. pseudoginseng , P. vietnamensis , American Panax quinquefolium ). Preferably, the ginseng used in the present invention is Panax ginseng ).

As used herein, the term " red ginseng " means produced by heating ginseng through steam or sun-dried, preferably steam.

The ginseng or red ginseng extract, which is an active ingredient of the present invention, includes an extract obtainable by a conventional extraction process known in the art. (C) a mixed solvent of the lower alcohol and water, (d) a solvent mixture of acetone (such as methanol, , (e) ethyl acetate, (f) chloroform, (g) butyl acetate or (h) 1,3-butylene glycol as an extraction solvent are included in ginseng or red ginseng extract. Preferably, the ginseng or red ginseng extract is obtained by using water, ethanol, or a mixed solvent of ethanol and water as an extraction solvent, and most preferably water obtained by using an extraction solvent.

It is obvious to those skilled in the art that the extract of the present invention can be used to obtain ginseng or red ginseng extract which exhibits substantially the same effect not only by the above-mentioned extraction solvent but also by other extraction solvent. In addition, the extract of the present invention includes not only the extract obtained by the above-mentioned extraction solvent, but also an extract obtained through a conventional purification process. For example, by separation using an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatographies (made for separation by size, charge, hydrophobicity or affinity), and the like, The fraction is also included in the ginseng or red ginseng extract of the present invention.

The ginseng or red ginseng extract of the present invention can be prepared in a powder state by an additional process such as vacuum distillation and freeze drying or spray drying.

"Saponin" used as another active ingredient in the present invention has the same meaning as ginsenoside, that is, ginsenoside, unless otherwise specified. The term " saponin " as used in the present invention preferably means ginsenoside inherent to ginseng or red ginseng. More preferably, the saponin used in the present invention is selected from the group consisting of (a) protopanaxadiol-based ginsenosides, i.e. ginsenosides Ra1-3, Rb1-3, Rc, Rd, Rg3, Rh2, Rs1 and Rs2, Nyl-ginsenosides Rb1-2, Rc and Rd; And (b) the ginsenosides of the protozoan tridentate, ginsenosides Re, Rf, Rg1-2 and Rh1.

The saponin used in the present invention may be saponin in a separated and purified form, but is preferably ginsenoside contained in powder or extract of ginseng or red ginseng. Namely, ginseng or powder or extract of red ginseng containing saponin can be used in the present invention.

According to a preferred embodiment of the present invention, the acid polysaccharide used in the present invention is isolated from ginseng or red ginseng and is selected from the group consisting of glucuronic acid, galacturonic acid, glucose, and arabinose ) And an acidic polysaccharide having a molecular weight of 12,000 to 450,000.

According to a preferred embodiment of the present invention, the active ingredient used in the present invention is characterized by promoting secretion of interferon-alpha (interferon-alpha) and interferon-y (interferon-y). Specifically, it promotes the secretion of interferon-alpha (interferon-alpha) and interferon-gamma (interferon-gamma), which have antiviral action, and thereby suppresses the growth of avian influenza virus, thereby decreasing the mortality rate of avian influenza virus infection.

According to another preferred embodiment of the present invention, the avian influenza virus is a strain H5N1 or H9N2, more preferably a strain H5N1.

The composition of the present invention may be prepared from a pharmaceutical composition, a neutraceutical composition or a food composition.

According to a preferred embodiment of the present invention, the composition of the present invention comprises (a) a pharmaceutically effective amount of the above-mentioned effective ingredient of the present invention; And (b) a pharmaceutically acceptable carrier.

As used herein, the term " pharmaceutically effective amount " means an amount sufficient to achieve efficacy or activity of the above-described effective ingredients of the present invention.

When the composition of the present invention is manufactured from a pharmaceutical composition, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier. The pharmaceutically acceptable carriers to be contained in the pharmaceutical composition of the present invention are those conventionally used in the present invention and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, it can be administered by intravenous injection, subcutaneous injection, muscle injection, intraperitoneal injection, percutaneous administration, mucosal administration, .

The appropriate dosage of the pharmaceutical composition of the present invention may vary depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate, . Preferably, the dosage of the pharmaceutical composition of the present invention is 0.001-100 mg / kg (body weight) on an adult basis.

The pharmaceutical composition of the present invention may be formulated into a unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container. The formulations may be in the form of solutions, suspensions, syrups or emulsions in oils or aqueous media, or in the form of excipients, powders, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.

When the composition of the present invention is prepared from a food composition (or a functional food composition), it includes not only the above-mentioned effective ingredient of the present invention, but also ingredients normally added in the course of food production. Examples thereof include proteins, carbohydrates, fats , Nutrients, flavoring agents, and flavoring agents. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. As a flavoring agent, natural flavoring agents such as tau martin and stevia extract (for example, rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharin, aspartame, etc.) can be used.

 For example, when the food composition of the present invention is prepared as a drink, it may further contain citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, have.

The features and advantages of the present invention are summarized as follows:

(I) Ginseng or red ginseng extract, saponin or acid polysaccharide used as an active ingredient of the present invention has excellent avian influenza virus proliferation inhibition and anti-avian influenza virus effect.

(Ii) The active ingredient used in the present invention promotes secretion of interferon-alpha (interferon-alpha) and interferon-gamma (interferon-gamma) involved in antivirus and inhibits the proliferation of avian influenza virus.

(Iii) these antiviral effects effectively reduce the mortality rate for avian influenza virus infection.

(Iv) Pharmaceutical, functional food or food compositions may also be prepared as active ingredients of the present invention.

As described in detail above, the present invention provides an anti-bird flu virus composition and an anti-avian influenza virus composition comprising ginseng or red ginseng extract, saponin or acid polysaccharide as an active ingredient. The active ingredient used in the present invention promotes the secretion of interferon-alpha (interferon-alpha) and interferon-gamma (interferon-gamma) involved in antivirus and inhibits the proliferation of avian influenza virus. This antiviral effect effectively reduces the mortality rate for avian influenza virus infection. In addition, pharmaceuticals, functional foods, or food compositions can be prepared as active ingredients of the present invention.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not to be construed as limiting the scope of the present invention. It will be self-evident.

Example

Materials and Methods

Experimental material

(100 mg / kg, Korean Ginseng Corp.) and saponin (50 mg / kg, Korea Ginseng Corp., Rg1 0.43 mg / g, Re 0.72 mg / g, Rf 1.06 mg / g, Rd 1.70 mg / g, Rg3 4.96 mg / g, Rb1 3.55 mg / g, Rb2 1.75 mg / g, Rc 1.81 mg / g, Rd 1.70 mg / g, Rg3 5.40 mg / g, Rh2 0.03 mg / And then orally administered to mice.

Red ginseng H5N1 The vaccine strain  Mortality analysis for infected mice

It is important to conduct studies on mortality to determine whether red ginseng samples are acting as immunosuppressants that protect mice from H5N1 avian influenza virus infection. 100 ml ₅₀ (50%) was administered to 10 mice (Balb / C, Sumatoco) daily at a dose of 100 mg / kg or 50 mg / kg of red ginseng samples (Korean Ginseng Corporation) The lethal dose of mouse lethal dose 50 (0.1 ml) was infected with the H5N1 vaccine strain (provided by the US CDC) into the nasal cavity, and the mortality was measured until 14 days after infection. Animals infected with virus without administration of red ginseng samples were used as control. Survival of mice was investigated and the results were analyzed.

Red ginseng H5N1 Vaccine strain  Virus for infected mice Potency  analysis

Studies on the effects of red ginseng samples on the activity of viruses that proliferate in lung tissues during influenza virus infection can be an important data to clarify the immune function - enhancing ability of red ginseng against avian influenza. 0.2 ml of water concentrate (100 mg / kg) and saponin (50 mg / kg) (Korea Ginseng Corp.) were administered to 15 mice every day for 30 days before viral infection and 100 MID ₅₀ (0.1 ml) of mouse infectious dose of the H5N1 vaccine strain was infected into the nasal cavity. Animals infected with virus without administration of red ginseng samples were used as control. Virus titers were obtained by administering samples daily for 30 days before virus infection, and then obtaining three mouse lungs on days 3, 5, 7 and 9 of infection to determine the virus titer to log ₁₀ EID ₅₀ / g (egg infectious dose 50) Respectively. It was also verified by immunohistochemistry using an influenza nucleoprotein (NP) antibody (Serotech). Virus titers and antigen positive counts were analyzed and the results were analyzed.

Red ginseng H5N1 Vaccine strain  Histopathological analysis of mice administered

The pathological changes of the lung tissues in influenza virus infection of red ginseng samples can be a direct testimony to the ability of red ginseng to immunize against avian influenza. 0.2 ml of red ginseng sample (prepared by KT & G Central Research Institute) was administered to mice 10 times daily for 30 days before viral infection, and H5N1 vaccine strain of 100 MID50 (mouse infectious dose 50) (0.1 ml) After the infection with the nasal cavity, lungs were obtained and pathological histological studies were performed. Histopathological examination was performed on day 3 for 30 days before viral infection, and mouse lung was obtained on days 3, 5, 7 and 9 of infection, and histological examination was performed with hematoxylin and eosin staining (H & E staining) . The histopathologic changes were analyzed and the results were analyzed.

Red ginseng H5N1 To the vaccine strain  Analysis of immunity mechanism

To investigate the mechanism by which red ginseng samples show immunity enhancement upon influenza virus infection, lung tissue was obtained and interferon-alpha and interferon-gamma (interferon-gamma) involved in antiviral activity were measured by ELISA. 0.2 ml of red ginseng sample (Korean Ginseng Corp.) was administered to mice 10 times daily for 30 days prior to viral infection, and the H5N1 vaccine of 100 MID ₅₀ (mouse infectious dose 50) (0.1 ml) After infecting the strain with nasal passages, lungs were obtained and the amount of interferon was measured. Animals infected with virus without administration of red ginseng samples were used as control. Histopathologic assays were performed on hematoxylin and eosin staining (H & E staining) by obtaining mouse lungs on days 3, 5, 7 and 9 after infection with the samples daily for 30 days prior to viral infection. The amount of interferon was measured by ELISA and the results were analyzed.

Experiment result

The vaccine strain  Results of mortality analysis on infected mice

As shown in FIG. 1, the control group showed 100% mortality until the 8th day of infection, but the red ginseng water extract group showed a survival rate of 60% as compared with the control group (virus-infected group without sample administration) Showed a survival rate of 50%. This result indicates that red ginseng has a preventive or protective effect against H5N1 avian influenza virus infection.

Specifically, in the group to which red ginseng was administered, the mice were killed by one mouse at 4, 6, 7 and 8 days after infection, and survival rate was 60%. In the group administered with saponin, 3 mice on the 4th day after infection, One dog died at day 1 and showed a survival rate of 50%. On the other hand, the control group died at 4 days after infection, 2 at day 5, 2 at day 6, 1 at day 7, and 1 at day 8 and showed 100% mortality.

Meanwhile, the mortality rate of mice infected with the H5N1 vaccine strain of red ginseng acid polysaccharide was as follows:

Experimental group Survival rate at 8 days after infection Infected group 0% Red ginseng acid polysaccharide 100 mg / kg group 40%

As shown in Table 1, the infection group (ie, control group) showed 100% mortality until the 8th day of infection, but the survival rate of the red ginseng acid polysaccharide treated group was 40%. The red ginseng acid polysaccharide showed lower survival rate than the red ginseng water extract and saponin treated group, but the result shows that the red ginseng acid polysaccharide also has a preventive or protective effect against H5N1 avian influenza virus infection.

Red ginseng H5N1 The vaccine strain  Virus proliferation inhibition effect on infected mice

As can be seen from FIG. 2, the virus treated with red ginseng showed less than 2 log viruses in the lung as compared with the control group. In addition, when saponin was administered, 1 log fewer viruses were detected than the control group.

Specifically, the viral load of the lungs of the red ginseng group was 4.29 log ₁₀ EID ₅₀ / ml after 3 days of infection, 3.8 log ₁₀ EID ₅₀ / ml after 5 days of infection, 3.12 log ₁₀ EID ₅₀ / ml after 7 days of infection, After 2.85 log ₁₀ EID ₅₀ / ml, it gradually decreased with time. The viral load of the lungs of the saponin treated group was 5.5 log ₁₀ EID ₅₀ / ml after 3 days of infection, 4.66 log ₁₀ EID ₅₀ / ml after 5 days of infection, 3.0 log ₁₀ EID ₅₀ / ml after 7 days of infection and 3.0 log ₁₀ EID ₅₀ / ml. On the other hand, the control group three days after infection of 6.56 log ₁₀ EID ₅₀ / ml, infection 5 days of 5.5 log ₁₀ EID ₅₀ / ml, infected after 7 days 5.5 log ₁₀ was EID ₅₀ / ml, infected 9 days are all mice died Virus titers could not be measured. Viruses of the red ginseng group on days 3, 5, and 7 of infection were statistically less effective than those of the control group (* indicates P value <0.05 and ** indicates P value <0.001).

As can be seen from FIG. 3, the virus antigen was confirmed using an influenza nuclear protein (NP) antibody in the mouse lung by immunohistochemistry. As a result, the number of influenza positive reactions in the lungs of mice administered with red ginseng was smaller than that of the control And saponin administration showed a smaller number of influenza positive than the control group.

Specifically, cells expressing influenza positive on the third day of infection were observed in the lungs of the control group, but not in the red ginseng and saponin treated groups (Fig. 3A). On day 5 of infection, influenza positive cells were observed in the control, red ginseng and saponin-treated groups (Fig. 3B). In addition, influenza-positive cells were observed in the saponin-treated group on the 7th day of infection, but influenza-positive cells were not observed in the red ginseng treated group, and all of the control groups died and immunohistochemistry was not performed (FIG. Influenza-positive cells were not observed in red ginseng and saponin-treated group on the 9th day of infection, and all of the control groups died and immunohistochemistry was not performed (FIG. 3D).

Red ginseng H5N1 The vaccine strain  Histopathological analysis of infected mice

As can be seen from FIG. 4, the mouse lung treated with red ginseng showed a weak inflammatory reaction compared to the control group by hematoxylin and eosin staining (H & E staining), and saponin- Inflammatory response was observed.

Specifically, compared with the normal lung (FIG. 4A), the control group and the saponin-treated group on the third day of infection showed infiltration of inflammatory cells such as lymphocytes, and the red ginseng administration group showed similar tissue structure to normal lungs (FIG. 4B) . On the 5th day after infection, the control and saponin-treated groups were infiltrated with multiple inflammatory cells and severe interstitial pneumonia symptoms, and the red ginseng group showed infiltration of minute inflammatory cells (FIG. 4c). On the 7th day after infection, the control group and the saponin-treated group had multiple inflammatory cells and interstitial pneumonia symptoms, and the red ginseng group showed weak interstitial pneumonia symptoms (Fig. 4d). On the 9th day after infection, all of the control groups died, and the saponin-treated group showed symptoms of inflammatory cell infiltration and interstitial pneumonia. The red ginseng group showed similar characteristics to normal lungs (FIG. 4A) (FIG.

Red ginseng H5N1 To the vaccine strain  Analysis of immunity mechanism of Korea

As shown in FIG. 5, in the mouse lung treated with the water extract of red ginseng on the third day of infection, interferon-alpha (Interferon-alpha) was secreted 3 times more than the control group and secreted more than saponin-administered mice . Even when interferon-γ was measured, red ginseng-treated mice were secreted to the lungs in a larger amount than in the control group. These results suggest that the mechanism by which red ginseng reduces mortality from avian influenza infection is due to the secretion of interferon-α and interferon-γ, which play antiviral roles.

Specifically, as shown in FIG. 5A, the secretion amount of interferon-.alpha. Was the highest in the red ginseng administration group on the third day of infection. On the third day of infection, 120.22 pg / g in the control group and 179.7 pg / g in the saponin administration group were 392.66 pg / g in the red ginseng administration group. On the 5th day after infection, the control group was 48.21 pg / g, saponin group was 62.23 pg / g and red ginseng group was 70.38 pg / g. At day 7 of infection, the control group was 2.42 pg / g, saponin group was 29.12 pg / g, and red ginseng group was 67.96 pg / g. On the 9th day, 12.69 pg / g in the saponin group and 36.24 pg / g in the red ginseng group, respectively. In the red ginseng group, many interferon-α were secreted statistically more effectively than the control group (P value <0.05).

As shown in FIG. 5B, the secretion of interferon-γ was highest in the red ginseng group on the 7th day of infection. On the third day of infection, the control group was 210.98 pg / g, saponin group was 257.07 pg / g, and red ginseng group was 355.19 pg / g. On the 5th day of infection, the control group was 195.73 pg / g, saponin group was 397.85 pg / g and red ginseng group was 492.28 pg / g. On the 7th day after infection, the control group was 266.63 pg / g, saponin group was 538.62 pg / g and red ginseng group was 565.1 pg / g. On the 9th day after infection, the saponins were 450.92 pg / g and the red ginseng group was 490.22 pg / g. In the red ginseng group, a lot of interferon-γ was secreted statistically more effectively than the control group (* indicates P value <0.05 and ** indicates P value <0.001).

From the results of the above experiment, it can be understood from the results of the study on the immunity enhancement against influenza virus of red ginseng using the H5N1 avian influenza vaccine strain and mouse, the red gins greatly reduce the mortality rate of the mouse, It is believed that this is because it suppresses influenza virus by promoting secretion of interferon having viral action.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

references

1. Seo, SH & RG Webster. Cross-reactive cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. J. of Virology 75: 2516-2525 (2001).

2. Seo, SH & RG Webster. Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J. of Virology 76: 1071-1076 (2002).

3. Seo, SH, Malik P., & RG Webster. The H5N1 influenza virus is associated with a proportion of pulmonary CD8 T cells. J. of Virology 76: 4886-4890 (2002).

4. Seo, SH, Hoffmann, E and Webster, RG Lethal H5N1 Influenza Viruses Escape Hostile-Viral Cytokine Responses. Nature Medicine 8 (9) 950-954 (2002).

5. Seo SH, Hoffmann E, Webster RG. The NS1 gene of H5N1 influenza viruses circumvents the host anti-viral cytokine responses. Virus Research 103: 107-113 (2004).

1 is a graph showing the effect of red ginseng used as an active ingredient of the present invention on the mortality rate of a mouse infected with the H5N1 vaccine strain. In Hongsam and saponin administration groups, mice were administered with 100 mg / kg of red ginseng water concentrate and 50 mg / kg of saponin, respectively. In the control group, mice infected with virus without administration of the red ginseng water concentrate and saponin it means.

2 is a graph showing the virus titer of mouse lungs administered with red ginseng used as an active ingredient of the present invention. * Indicates a P value < 0.05 and ** indicates a P value < 0.001.

Figures 3a-3d are photographs showing immunohistochemical staining of mouse lungs against influenza nucleoprotein (NP) antibodies. Arrows indicate cells that are positive for influenza. 3 dpi (Fig. 3a), 5 dpi (Fig. 3b), 7 dpi (Fig. 3c) and 9 dpi (Fig. 3d) show 3 days, 5 days, 7 days and 9 days after infection with the H5N1 vaccine strain.

Figures 4a-4e are photographs showing immunohistochemical staining for histopathological chemistry studies. H & E stain represents hematoxylin and eosin staining, and Uninfected Control represents normal lung (Fig. 4A). 3 dpi (Fig. 4B), 5 dpi (Fig. 4C), 7 dpi (Fig. 4D) and 9 dpi (Fig. 4E) show 3 days, 5 days, 7 days and 9 days after infection with the H5N1 vaccine strain.

5A and 5B are graphs showing interferon contents of mouse lungs administered with red ginseng used as an active ingredient of the present invention. * Indicates a P value < 0.05 and ** indicates a P value < 0.001. Fig. 5A is a graph showing interferon-alpha and Fig. 5B is a graph showing the secretion amount of interferon-y.

Claims (5)

A composition for inhibiting the proliferation of avian influenza virus comprising ginseng or red ginseng extract, ginseng saponin, or red ginseng acid polysaccharide as an active ingredient. An avian influenza virus composition comprising ginseng or red ginseng extract, ginseng saponin or red ginseng acid polysaccharide as an active ingredient. 3. The composition according to claim 1 or 2, wherein the active ingredient promotes secretion of interferon-alpha and interferon-gamma. 3. The composition according to claim 1 or 2, wherein the avian influenza virus is an H5N1 or H9N2 strain. The composition of claim 1 or 2, wherein the composition is a pharmaceutical composition, a neutraceutical composition, or a food composition.

Images